Skip to main content
. 2020 Dec 11;35(1):75–87. doi: 10.1007/s40259-020-00456-5

Fig. 1.

Fig. 1

Biosimilar infliximab market shares for the ten historical regions in England, calculated as volume (defined daily doses) of the biosimilars over volume of the biosimilars plus reference product, from 2015 to 2018